Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Weekly News Recap #Phispers
Annual Reports
NA
Finished Drug Prices
NA
1. 2-isopropyl-5-(2-phenylethenyl)benzene-1,3-diol
2. 3,5-dh4is
3. 5-(2-phenylethenyl)-2-isopropyl-1,3-benzenediol
4. Benvitimod
5. Gsk2894512
6. Tapinarof
7. Wbi-1001
1. Benvitimod
2. Tapinarof
3. 79338-84-4
4. Wbi-1001
5. Gsk2894512
6. Vtama
7. Wbi 1001
8. Tapinarof [usan]
9. 3,5-dihydroxy-4-isopropyl-trans-stilbene
10. (e)-2-(1-methylethyl)-5-(2-phenylethenyl)-1,3-benzenediol
11. 2-isopropyl-5-styrylbenzene-1,3-diol
12. Gsk-2894512
13. 5-[(e)-2-phenylethenyl]-2-propan-2-ylbenzene-1,3-diol
14. (e)-2-isopropyl-5-styrylbenzene-1,3-diol
15. 84hw7d0v04
16. Tapinarof (usan)
17. 1,3-benzenediol, 2-(1-methylethyl)-5-[(1e)-2-phenylethenyl]-
18. 115781-08-3
19. 1,3-benzenediol, 2-(1-methylethyl)-5-(2-phenylethenyl)-, (e)-
20. 3,5-dh4is
21. Unii-84hw7d0v04
22. 1,3-benzenediol, 2-(1-methylethyl)-5-((1e)-2-phenylethenyl)-
23. Benvitimod (tapinarof)
24. Tapinarof [inn]
25. Tapinarof [who-dd]
26. Schembl918343
27. Chembl259571
28. Gtpl9686
29. Dtxsid301045262
30. Bcp13569
31. Ex-a4877
32. Zinc5761533
33. (e)-4-isopropylstilbene-3,5-diol
34. Mfcd13193203
35. S9700
36. Akos025296109
37. Db06083
38. Wb-1001
39. Ac-36567
40. As-44364
41. Hy-109044
42. Cs-0031487
43. D11365
44. A914284
45. Q4634086
46. 2-(1-methylethyl)-5-[(e)-2-phenylethenyl]benzene-1,3-diol
47. 2-(1-methylethyl)-5-((1e)-2-phenylethenyl)-1,3-benzenediol
48. 5-((1e)-2-phenylethen-1-yl)-2-(propan-2-yl)benzene-1,3-diol
Molecular Weight | 254.32 g/mol |
---|---|
Molecular Formula | C17H18O2 |
XLogP3 | 4.6 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 2 |
Rotatable Bond Count | 3 |
Exact Mass | 254.130679813 g/mol |
Monoisotopic Mass | 254.130679813 g/mol |
Topological Polar Surface Area | 40.5 Ų |
Heavy Atom Count | 19 |
Formal Charge | 0 |
Complexity | 280 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 1 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in psoriasis and psoriatic disorders.
WBI-1001 selectively modulates the cytokine cascade deep under the skin, a process that rapidly decreases inflammations and skin plague. It targets the four major mechanisms involved in the disease.
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.
NDC Package Code : 64552-4104
Start Marketing Date : 2023-01-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.
NDC Package Code : 58175-0646
Start Marketing Date : 2022-03-15
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 40261
Submission : 2024-07-31
Status : Active
Type : II
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
RLD : Yes
TE Code :
Brand Name : VTAMA
Dosage Form : CREAM;TOPICAL
Dosage Strength : 1%
Approval Date : 2022-05-23
Application Number : 215272
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
Patent Expiration Date : 2038-11-13
US Patent Number : 10647649
Drug Substance Claim : Y
Drug Product Claim :
Application Number : 215272
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2038-11-13
Patent Expiration Date : 2036-05-19
US Patent Number : 10426743
Drug Substance Claim :
Drug Product Claim :
Application Number : 215272
Patent Use Code : U-2625
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2036-05-19
Patent Expiration Date : 2036-05-19
US Patent Number : 11612573
Drug Substance Claim :
Drug Product Claim :
Application Number : 215272
Patent Use Code : U-2625
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2036-05-19
Patent Expiration Date : 2039-11-13
US Patent Number : 11590088
Drug Substance Claim :
Drug Product Claim :
Application Number : 215272
Patent Use Code : U-2625
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2039-11-13
Patent Expiration Date : 2036-05-19
US Patent Number : 11458108
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 215272
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2036-05-19
Patent Expiration Date : 2036-05-19
US Patent Number : 11622945
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 215272
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2036-05-19
Patent Expiration Date : 2036-05-19
US Patent Number : 10195160
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 215272
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2036-05-19
Patent Expiration Date : 2038-11-13
US Patent Number : 11597692
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 215272
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2038-11-13
Patent Expiration Date : 2036-05-19
US Patent Number : 11617724
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 215272
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2036-05-19
ABOUT THIS PAGE
A Tapinarof manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Tapinarof, including repackagers and relabelers. The FDA regulates Tapinarof manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Tapinarof API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Tapinarof manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Tapinarof supplier is an individual or a company that provides Tapinarof active pharmaceutical ingredient (API) or Tapinarof finished formulations upon request. The Tapinarof suppliers may include Tapinarof API manufacturers, exporters, distributors and traders.
click here to find a list of Tapinarof suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Tapinarof DMF (Drug Master File) is a document detailing the whole manufacturing process of Tapinarof active pharmaceutical ingredient (API) in detail. Different forms of Tapinarof DMFs exist exist since differing nations have different regulations, such as Tapinarof USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Tapinarof DMF submitted to regulatory agencies in the US is known as a USDMF. Tapinarof USDMF includes data on Tapinarof's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Tapinarof USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Tapinarof suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Tapinarof as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Tapinarof API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Tapinarof as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Tapinarof and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Tapinarof NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Tapinarof suppliers with NDC on PharmaCompass.
Tapinarof Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Tapinarof GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Tapinarof GMP manufacturer or Tapinarof GMP API supplier for your needs.
A Tapinarof CoA (Certificate of Analysis) is a formal document that attests to Tapinarof's compliance with Tapinarof specifications and serves as a tool for batch-level quality control.
Tapinarof CoA mostly includes findings from lab analyses of a specific batch. For each Tapinarof CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Tapinarof may be tested according to a variety of international standards, such as European Pharmacopoeia (Tapinarof EP), Tapinarof JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Tapinarof USP).
LOOKING FOR A SUPPLIER?